VIVUS fundamentals

Use VIVUS Inc fundamentals together with your other stock asset holdings to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.  Optimize Portfolio

VIVUS Inc is rated below average in one year high category among related companies. It is rated below average in return on equity category among related companies .

One Year High

Return On Equity Return On Asset Current Valuation Shares Outstanding Shares Owned by Insiders Shares Owned by Institutions Number of Shares Shorted Price to Earning Price to Book Price to Sales Revenue Gross Profit EBITDA Net Income Cash and Equivalents Cash per Share Current Ratio Book Value Per Share Cash Flow from Operations Short Ratio One Year High One Year Low Earnings Per Share Price to Earnings To Growth Number of Employees Beta Market Capitalization Total Asset Retained Earnings Working Capital Current Asset Current Liabilities Z Score Probability Of Bankruptcy

VIVUS competes with GILEAD, AMGEN, CELGENE, BIOGEN, and REGENERON. VIVUS Inc offers Qsymia, a drug for the treatment of obesity as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weightrelated comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. VIVUS Inc has an agreement with Mitsubishi Tanabe Pharma Corporationration for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.